Literature DB >> 11533965

Effect of DHA-containing formula on growth of preterm infants to 59 weeks postmenstrual age.

Alan S. Ryan1, Michael B. Montalto, Sharon Groh-Wargo, Francis Mimouni, Joan Sentipal-Walerius, Jeanine Doyle, Joel S. Siegman, Alicia J. Thomas.   

Abstract

Between May 1993, and September 1994, a randomized, blinded clinical trial was conducted to evaluate measures of growth and body composition in 63 (32 males; 31 females) healthy, low-birth-weight infants (940-2250 g) who were randomly assigned to an infant formula with docosahexaenoic acid (22:6n3, DHA, 0.2 wt%) from fish oil or to a control formula. A preterm formula with or without DHA was fed beginning at 7-10 days prior to hospital discharge through 43 weeks postmenstrual age (PMA). Then, from 43-59 weeks PMA, infants were fed a term infant formula with or without a corresponding amount of DHA. Growth (weight, length, head circumference), regional body fatness (triceps, subscapular, suprailiac skinfold thicknesses), circumferences (arm, abdominal, chest), and estimates of body composition determined by total body electrical conductivity (TOBEC) (fat-free mass [FFM]) were evaluated. Growth was slower in males fed the DHA formula. They had significantly (P < 0.05) smaller gains in weight, length, and head circumference between study enrollment to 59 weeks PMA than those fed the control formula. At 51 weeks PMA, males in the DHA group had significantly smaller head circumferences (P < 0.05) and lower FFM (P < 0.05). At 59 weeks PMA, males in the DHA group weighed less (P < 0.05), had shorter recumbent lengths (P < 0.01), smaller head circumferences (P < 0.05), and lower FFM (P < 0.01) than those fed the control formula. Energy intakes from formula (kcal/d), however, were lower at 51 weeks (P < 0.05) and 59 weeks (P < 0.05) PMA in males fed the DHA formula. Adjusted for body weight (kcal/kg/d), mean energy intakes from formula at 51 and 59 weeks PMA were not significantly different between feeding groups. The differences in recumbent length, head circumference, and FFM remained statistically significant after controlling for energy and protein intakes (P < 0.01). For all males, neither FFM nor total body fat (TBF), when expressed as a percentage of total body weight, differed significantly between feeding groups. Among females, there were no significant differences between the feeding groups in measures of growth, body composition, or energy intake. The results indicated that infant formula with fish oil containing DHA and EPA in a 5:1 ratio had a significant, negative effect on growth and body composition in males during the first 6 months of life. It is not clear why the growth deficits were limited to males and not females. The eicosanoids, bioactive metabolites of omega-3 and omega-6 fatty acids, may mediate several important growth hormones. The present results do not support the addition of DHA alone in infant formulas. Am. J. Hum. Biol. 11:457-467, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Year:  1999        PMID: 11533965     DOI: 10.1002/(SICI)1520-6300(1999)11:4<457::AID-AJHB5>3.0.CO;2-B

Source DB:  PubMed          Journal:  Am J Hum Biol        ISSN: 1042-0533            Impact factor:   1.937


  10 in total

1.  Docosahexaenoic and Arachidonic Acid Supplementation of Toddlers Born Preterm Does Not Affect Short-Term Growth or Adiposity.

Authors:  Taniqua T Ingol; Rui Li; Kelly M Boone; Joseph Rausch; Mark A Klebanoff; Abigail Norris Turner; Keith O Yeates; Mary Ann Nelin; Kelly W Sheppard; Sarah A Keim
Journal:  J Nutr       Date:  2019-12-01       Impact factor: 4.798

Review 2.  Polyunsaturated fatty acids and infant growth.

Authors:  A Lapillonne; S E Carlson
Journal:  Lipids       Date:  2001-09       Impact factor: 1.880

3.  Randomized trials with polyunsaturated fatty acid interventions in preterm and term infants: functional and clinical outcomes.

Authors:  R A Gibson; W Chen; M Makrides
Journal:  Lipids       Date:  2001-09       Impact factor: 1.880

4.  Breast milk fatty acid composition differs between overweight and normal weight women: the STEPS Study.

Authors:  Johanna Mäkelä; Kaisa Linderborg; Harri Niinikoski; Baoru Yang; Hanna Lagström
Journal:  Eur J Nutr       Date:  2012-05-26       Impact factor: 5.614

Review 5.  Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy.

Authors:  Tim Schindler; John Kh Sinn; David A Osborn
Journal:  Cochrane Database Syst Rev       Date:  2016-10-28

6.  Omega-3 fatty acid supplementation during pregnancy: for mother, baby, or neither?

Authors:  Gal Dubnov-Raz; Yaron Finkelstein; Gideon Koren
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

7.  Fish oil prevents essential fatty acid deficiency and enhances growth: clinical and biochemical implications.

Authors:  Robert A M Strijbosch; Sang Lee; Danielle A Arsenault; Charlotte Andersson; Kathleen M Gura; Bruce R Bistrian; Mark Puder
Journal:  Metabolism       Date:  2008-05       Impact factor: 8.694

8.  Human placental transcriptome shows sexually dimorphic gene expression and responsiveness to maternal dietary n-3 long-chain polyunsaturated fatty acid intervention during pregnancy.

Authors:  Eva-Maria Sedlmeier; Stefanie Brunner; Daniela Much; Philipp Pagel; Susanne E Ulbrich; Heinrich Hd Meyer; Ulrike Amann-Gassner; Hans Hauner; Bernhard L Bader
Journal:  BMC Genomics       Date:  2014-10-27       Impact factor: 3.969

9.  SMOFlipid Impact on Growth and Neonatal Morbidities in Very Preterm Infants.

Authors:  Suzan S Asfour; Belal Alshaikh; Latifah AlMahmoud; Haider H Sumaily; Nabeel A Alodhaidan; Mousa Alkhourmi; Hissah A Abahussain; Thanaa M Khalil; Bushra A Albeshri; Aroub A Alhamidi; Maha R Al-Anazi; Raneem S Asfour; Mountasser M Al-Mouqdad
Journal:  Nutrients       Date:  2022-09-23       Impact factor: 6.706

Review 10.  The Essentiality of Arachidonic Acid in Infant Development.

Authors:  Kevin B Hadley; Alan S Ryan; Stewart Forsyth; Sheila Gautier; Norman Salem
Journal:  Nutrients       Date:  2016-04-12       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.